A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan

Clinical Biochemistry

Volumn 41, Issue 3, 2008, Pages 121-125

  Lee, Su Chen ^a   Hou, Ming Feng ^a   Hsieh, Pei Chen ^b   Wu, Szu Hsien ^c,d   Ann Hou, Linda ^e   Ma, Hsu ^c,d   Tsai, Shin Meng ^b   Tsai, Li Yu ^b  

^a Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Breast cancer; HER2 I655V genotype; PCR RFLP

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ISOLEUCINE; VALINE;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TAIWAN;

ADULT; AGE FACTORS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ISOLEUCINE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES; RISK FACTORS; TAIWAN; VALINE;

EID: 38649129767     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.11.005     Document Type: Article

References (27)

1. Tommasi S., Fedele V., Lacalamita R., et al. Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Lett 209 (2004) 215-222
2. Prenzel N., Fischer O.M., Streit S., Hart S., and Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8 (2001) 11-31
3. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 (2000) 3159-3167
4. Kokai Y., Myers J.N., Wada T., et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58 (1989) 287-292
5. Spencer K.S., Graus-Porta D., Leng J., Hynes N.E., and Klemke R.L. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol 148 (2000) 385-397
6. Bartlett J.M., and Forsyth A. HER2 FISH in breast cancer. Methods Mol Med 97 (2004) 89-101
7. Varga Z., Zhao J., Ohlschlegel C., Odermatt B., and Heitz P.U. Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology 44 (2004) 332-338
8. Ross J.S., Fletcher J.A., Linette G.P., et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8 (2003) 307-325
9. Cooke T., Reeves J., Lanigan A., and Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 12 Suppl 1 (2001) S23-S28
10. Papewalis J., Nikitin A., and Rajewsky M.F. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 19 (1991) 5452
11. Benusiglio P.R., Lesueur F., Luccarini C., Ponder B.A., et al. Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 7 (2005) R204-R209
12. Frank B., Hemminki K., Wirtenberger M., et al. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis 26 (2005) 643-647
13. Xie D., Shu X.O., Deng Z., et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92 (2000) 412-417
14. Millikan R., Eaton A., Worley K., et al. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 79 (2003) 355-364
15. Montgomery K.G., Gertig D.M., Baxter S.W., et al. The HER2 I655V polymorphism and risk of breast cancer in women age 40 years. Cancer Epidemiol Biomarkers Prev 12 (2003) 1109-1111
16. Wang-Gohrke S., and Chang-Claude J. Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93 (2001) 1657-1659
17. Keshava C., McCanlies E.C., Keshava N., Wolff M.S., and Weston A. Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 173 (2001) 37-41
18. Ameyaw M.M., Thornton N., and McLeod H.L. Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92 (2000) 1947
19. Hishida A., Hamajima N., Iwata H., et al. Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 94 (2002) 1807-1808
20. Baxter S.W., and Campbell I.G. Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93 (2001) 557-559
21. Nelson S.E., Gould M.N., Hampton J.M., and Trentham-Dietz A. A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res. 7 (2005) R357-R364
22. Rutter J.L., Chatterjee N., Wacholder S., and Struewing J. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology 14 (2003) 694-700
23. Kamali-Sarvestani E., Talei A.R., and Merat A. Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett 215 (2004) 83-87
24. Papewalis J., Nikitin A., and Rajewsky M.F. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res. 19 (1991) 5452
25. Pinto D., Vasconcelos A., Costa S., et al. HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev 13 (2004) 177-181
26. Zubor P., Vojvodova A., Danko J., et al. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. Neoplasma 53 (2006) 49-55
27. Morrison C., Zanagnolo V., Ramirez N., et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24 (2006) 2376-2385